Earlier-phase studies indicated that the drug may help reduce liver fat in people with obesity, potentially slowing the progression of NAFLD
Click for Full Disclaimer What to Expect From a GLP-1 Therapy Program A clear, provider-guided process focused on safety, support, and steady progress
One major difference between the two types of GLP-1s is dosage
The rate of weight gain after drug discontinuation was not dependent on the level of support provided during the period after medication discontinuation
Food and Drug Administration announced it will take enforcement action against non-FDA-approved compounded GLP-1 drugs that are being mass-marketed as alternatives to FDA-approved therapies
Early results from ongoing clinical studies are indicating the GLP-1 medications may successfully treat numerous other conditions including non-alcoholic fatty liver disease (known as metabolic dysfunction-associated steatohepatitis or MASH), sleep apnea, heart failure, diabetic kidney disease and Alzheimers disease